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Introduction
Today pharmaceutical policy is a 
global concern, with the overall goal of 
achieving rational medicines use. Such goal 
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makes policy analysis issues dynamic and 
constantly under evolution.1 Pharmaceutical 
policy is both problem solving and policy 
making. So policy analysis is both a tool 
of the problem-solving process and the 
democratic process.2 It is the process of 
predicting impacts of possible policies 
and evaluating past policies.1 The value 
of policy analysis lies in its contribution 
to the understandings that citizens have 
of issues and therefore to the making of 
policies with outcomes supported by the 
public. 2
Pharmaceutical policies made on 
national, international, supranational 
or global level, will always ultimately 
affect everyone. The Europeanisation 
of medicines regulation harmonises 
the standards of regulatory evaluation 
in order to accommodate a single 
European pharmaceutical market, and 
thus eliminates conflicting regulatory 
decisions made by national authorities in 
the European Union (EU).1 Member states 
have the challenge of strengthening their 
capacity to manage the complexities 
of relevant trends, options for change, 
evidence assessment, setting of priorities, 
drafting and implementing action plans, 
measuring outcomes and taking corrective 
action.4 
Following EU accession in May 2004, 
Malta faced its own challenges in the 
pharmaceutical area. Accession brought 
with it a change in the legislation 
regarding medicinal products for human 
use (Table 1). EU legislation regarding 
good manufacturing practice, importation 
and parallel importation, marketing 
authorisations, packaging and labeling, 
wholesale distribution, reimbursement 
and selection of medicines, clinical trials, 
pharmacovigilance and advertising had to 
be transposed into the Maltese legislation. 
Thus, new regulations were established. 
The quality, access, and rational use 
of medicines were effected, especially by 
the newly introduced procedures by which 
medicinal products are placed on the 
Maltese market. Between 1998 and 2002 
the procedure involved the submission 
of a World Health Organisation (WHO) 
Certificate of Pharmaceutical Product 
(CPP). Products registered with a CPP 
were included in the transition list which 
was drawn up in November 2002. The 
products were bound to benefit from 
a derogation. The derogation period 
in which products in the transition 
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list could be registered via a Provisional 
Marketing Authorisation (PMA) followed by 
a Marketing Authorisation (MA), ended in 
December 2006. 
Upon accession into the EU, medicinal 
products could be placed on the Maltese 
market not only through the PMA-MA 
process but also through the Mutual 
Recognition Procedure (MRP). From February 
200 Article 126a of Directive 2001/8 on 
the Community code relating to medicinal 
products for human use, as amended by 
Directive 2004/2/EC of the European 
Parliament and of the council of 1st 
March 2004, could be used, while starting 
from November 200, the Decentralised 
Procedure (DCP) could also be used.6
A legislative framework is necessary 
for the implementation and enforcement 
of policies. The legal basis for the control 
of activities in the public and private 
pharmaceutical sectors can only be 
provided by legislation and regulations. EU 
legislation can and does have an impact on 
medicines and health. On the other hand, 
national governments attempt to retain 
control.8
Public oversight and stewardship 
are required for the production and 
distribution of medicines (Table 2). Unlike 
other goods and services, medicines 
have to be regulated so that the market 
is successful and safe for the users.11 
Medicines regulation operates within 
a legal framework and is based on the 
application of medical, scientific and 
technical knowledge and skills. It involves 
interactions with various stakeholders whose 
economic, social and political motives 
may differ, making the implementation of 
regulation quite challenging.12
An efficient regulatory system for 
medicines provides timely access to 
effective treatments for patients and 
protects patient safety. The patients, 
doctors, pharmacists, government and the 
pharmaceutical industry share a common 
interest which is ensuring that the system 
is efficient, transparent and robust and 
makes decisions based on sound scientific 
evidence.1 They access quality and 
rational use of medicines depend on such a 
regulatory system. 
The issue of the impact of EU 
legislation on the access, quality and 
rational use of medicines was looked at 
from three approaches so as to obtain a 
holistic picture. The types and number 
of authorisations were reviewed, local 
newspapers were scanned, and group 
discussions with major stakeholders were 
held. 
The impact was multifaceted. The 
regulatory changes triggered actions and 
reactions from the main stakeholders 
including the Malta Chamber of Pharmacists, 
the Malta Chamber of Commerce and 
Enterprise (CoCE), the Malta Chamber for 
Small and Medium Enterprises (GRTU), 
the Federation of Industry (FOI) and the 
government. The affects of EU legislation 
on the various pharmaceutical areas 
were discussed, agreements reached and 
necessary action taken to amend and 
improve the situation. 
Quality	of	medicines
Poor quality medicines are ineffective, 
harmful and can result in therapeutic 
failure. The availability of high quality 
medicines promotes and ensures confidence 
in health systems, health professionals, 
pharmaceutical manufacturers and 
distributors. A strong national regulatory 
authority is the key to the effective 
regulation of manufacture, trade and use of 
medicines and therefore the protection and 
promotion of public health.12
Prior to accession, Malta had 020 EU 
and non-EU products placed on the market 
via a WHO CPP. The latter was not enough 
to ensure the good quality, safety and 
efficacy of medicines available in Malta.14 
EU regulatory regime and the registration of 
medicinal products via PMA, MA, 126a, MRP 
or DCP brought with it an improvement in 
the quality, safety and efficacy of products 
(Table ).
  The implementation of EU legislation 
was considered a painful process which 
safeguards the community, by ensuring that 
the medicines available are of a certain 
standard and quality and of known impact 
on patients. Non-EU generic products may 
be of good quality but the EU legislation 
and standards provide safeguards for 
professionals and patients.
However, there is not sufficient 
scientific evidence in terms of patient 
outcomes to support this claim of better 
quality and therefore better outcomes in 
Malta. In spite of complaints on the drugs 
which were available in the years previous 
Table	1.	Maltese	pharmaceutical	legislation
Legislation	covering	medicinal	products	and	pharmaceutical	activities	in	Malta
1. The Medicines Act, 200, and its subsidiary legislation 
 (mainly covers regulation of medicines and pharmaceutical activities)
2. Dangerous Drugs Ordinance 199 (narcotic drugs)
. Medical and Kindred Professions Ordinance 1901 (psychotropic substances)
Table	2.	Pharmaceutical	Regulatory	Bodies
Bodies	safeguarding	the	quality,	access	and	rational	use	of	medicines	in	Malta
The Medicines	Authority (MA) in Malta is the National Competent Authority for the 
regulation of medicines for human use and has the mission “to contribute to the 
protection of public health in Malta through regulation of the safety, quality and 
efficacy of medicines for sale or supply on the Maltese market.”9 
The Pharmaceutical	Unit, within the Public Health Regulation Division of the 
Ministry for Social Policy, is responsible for and co-ordinates the administrative and 
technical aspects of legislation, policies and guidelines regarding pharmaceutical 
policy on a national level.10 
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to EU accession, the quality of the drugs in 
question was never checked. 
Access	to	good	quality	medicines
Access is defined as the ability to 
obtain health care, as determined by factors 
such as the availability and affordability 
of goods and services.1 Medicines can be 
essential to save lives, reduce suffering, 
and improve the functioning and well-
being of people who have access to them. 
Access to affordable and appropriately used 
high-quality medicines boosts both the 
productivity and economy. 
Availability	
Post-EU accession, the number of 
medicinal products which had a marketing 
authorization in Malta, was quite less than 
the approximate 0 products which were 
previously available on the market (Table 
). EU legislation and medicines registration 
caused a negative impact on the availability 
of medicine, as confirmed by Galea in 
September 200.14 Some stakeholders 
blamed EU directives for the reduction in 
medicines availability because importers 
and their suppliers failed to register new 
medicines, while others believed shortages 
were increasing from pre accession and 
continued post accession. Following the 
stakeholders indication of the need for a 
system that guarantees availability and 
choice, the government set up a commission 
to study medicine status and give 
recommendations. Eventually, authorization 
via 126a was introduced and registration 
fees were amended so as to improve 
availability and promote competition.
Labelling	and	packaging
Stakeholders were concerned with the 
cost implications of the labeling regulations 
Table	3.	Authorisations	issued	for	medicinal	products	in	Malta
Period
Type	of	authorization	
or	medicinal	product	list
Number	
May	2004
Derogation List / 
WHO CPPa
182 different active ingredients
020 medicinal products
162 medicinal products from EU
0 medicinal products on the private market
Up	to	December	2004 PMAb 2200 medicinal products
Year	2005
MRPc 6% (108 out of 10 applications)
DCPd % (1 out of 22 applications)
January	to	May	2006
MRP 10% (22 out of 211 applications)
DCP % ( out of 14 applications)
May	2006
PMA 220 medicinal products
MAe 
0 medicinal products
1299 under process
November	2006 126a listf 
16 medicinal products
6 active ingredients
Up	to	March	2007
126a authorisationsg
 authorisations 
10 applications under process
MA
14 from PMA-MA process
148 from MRP process
19 from line extensions (PMA-MA)
1 national
MRP/DCP 12 under process
Unlicensedh 12 medicinal products
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a. World Health Organisation Certificate of Pharmaceutical Product;
b. Provisional Marketing Authorisation; 
c. Mutual Recoginition Procedure; 
d. Decentralised Procedure; 
e. Marketing Authorisation; 
f. list of medicinal products with no authorisation and therefore medicinal products not marketed in Malta. N.B. Some were 
being imported directly by the Government Pharmaceutical Services through Article 20 of Medicines Act, 200; 
g. authorisation through Article 126a of Directive 2001/8 as amended by Directive 2004/2/EC; 
h. authorisation for the use of products which are not registered in Malta in line with DH Circular 20/06 Guidelines for the 
supply of medicinal products for human use through processes which are not covered by the Medicines Act, 200 and its 
subsidiary legislation.
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requirements. Labelling issues could have 
induced companies not to register products 
thus resulting in reduced availability and 
increased prices. The language issue was 
solved by an agreement to have either 
one of the two official national languages, 
Maltese or English, used for packaging and 
labelling. 
Registration	system	
and	registration	fees
EU accession brought with it what has 
been called a cumbersome bureaucratic 
registration process, as predicted in the 
study by Vella Bonanno (200). Malta 
suffered a shortage of medicines because 
the pharmaceutical companies were finding 
it too expensive to register their products 
for a small market of 400,000 people. 
The government had been assured 
that registration costs were not high. But, 
pharmaceutical companies withdrew due 
to labour intensive, disproportionate costs 
and registration fees. The stakeholders 
were concerned with the impact that the 
strict implementation of EU legislation was 
having on the access to medicines. On the 
other hand, the well-run registration system 
attracted pharmaceutical manufacturers 
to Malta, as it provided the necessary 
regulatory support crucial for sustaining the 
local industry.
Eventually, the EU introduced a clause 
to overcome the problem of reduced 
availability through the issuing of a 
qualified licence (authorization via article 
126a). However, up to mid May 2006, no 
one had applied for this simpler registration 
procedure. The industry had to be pressured 
for medicines to be registered in Malta. 
Between January 200 and June 2006, 
Malta was included only in 10 applications 
for MRP and in 8 applications for DCP. The 
problem of high registration and variation 
fees was solved by an agreement on a 
system of uncomplicated fees comprising 
only a Lm0 (€116.4) annual registration 
fee. 
Local	manufacturing	industry
EU legislation provided strong support 
through the Medicines Authority for the 
local manufacturing industry, and the latter 
grew steadily as the benefits of the local 
industry were adequately acknowledged 
and safeguarded. Discussions led to the 
provision of a mechanism which ensures 
availability and overall reduced prices for 
the local consumers, while still keeping 
the regulatory frameworks which govern 
medicinals in Malta.
Affordability/pricing
Upon EU accession, the prices of 
medicines in Malta increased drastically. 
Cheap reasonably priced medicines were 
replaced by expensive ones. The mark-ups 
for the wholesale dealer and pharmacists 
were no longer regulated and instead 
were left up to market forces. Where, due 
to these same market forces, only one 
medicine is available, monopoly resulted. 
The regulatory system was blamed for 
the elimination of competitor products so 
that originator more expensive products 
remain. Availability and affordability are 
highly linked as decreased number of 
products leads to decreased competition 
and therefore increased prices.14 The need 
to promote the use of generics became 
evident, as this would cut down costs 
and increase choice and accessibility. 
Discussions led to consideration of 
reference pricing to control prices and of 
a system which favours the importation 
of generics. The Consumer Competition 
Division (CCD) within the former Ministry 
for Competitiveness and Communications 
(MCMP) was to monitor prices and 
discussions were held to establish a system 
whereby action could be taken as necessary 
to induce the market forces to interact and 
thus abolish price increases. 
Rational	use	of	medicines
WHO states that rational use requires 
patients to receive medications appropriate 
to their needs, in doses that meet individual 
requirements, for an adequate period of 
time, and at the lowest possible cost. This 
is essential for the promotion of quality 
care and cost-effective therapy. Rational use 
ensures that medicines are used only when 
needed and that patients understand what 
medicines are for and how to use them.16 At 
the same time the concept of rational use of 
medicines should be applied in a contextual 
manner.1 
Pricing,	internet,	counterfeit	medicines
The problem of expensive medicines 
is at times solved by buying through the 
internet at one third of the local price 
because all one needs is a prescription. This 
aids rational use as doctors can prescribe 
medicines recommended by clinical 
guidelines even if they are not available 
on the Maltese market or are too expensive 
for low-income patients. However, the 
significant risk of counterfeit medicines 
exists. In Malta there is not enough 
awareness on this problem, and it is of 
concern that prescribers are recommending 
online buying to patients.
 
Availability	and	choice
The rational use of medicines 
in Malta, though supported by the 
new legislation, was limited by the 
unavailability of medicines resulting from 
the implementation of this same legislation. 
Following EU accession there was a reduced 
consumer choice of children’s medicine and 
of dosage types. Consumers did not find 
their medicines and believed they were 
being offered inferior alternatives. 
Compared to the British National 
Formulary (BNF), the Malta Medicines List 
(MML) was limited thus affecting choice 
and rational use of medicines.18 Similarly, 
the Government Formulary List (GFL) was 
also considered to be limited.19 However, 
following EU accession, the transposition 
of the Transparency Directive (EU Council 
Directive 89/10/EEC of 21st December 
1988) gave the medicines agents the 
possibility of having their products 
introduced on the list.20 
Culture,	habits	and	practice
The medicines available through EU 
brought to the fore issues of changes in 
practice e.g. the use of suppositories, when 
most other EU countries use tablets, soluble 
tablets or syrup. Authorisation via 126a aids 
maintenance of usual preparations when a 
change in culture, habit or practice is not 
accepted. 
Regulatory/Policy
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Generics,	rational	prescribing	
and	substitution
The EU system ensures generics are 
chemically, biologically and clinically 
equivalent, and of high quality and so can 
be used with full confidence. The local 
industry argued that the promotion of 
generic dispensing, patient awareness on 
generics and knowledge on the available 
generic substitutes would ensure rational 
use and affordability. In Malta the use of 
generics is supported by legislation which 
allows substitution of medicines so that 
pharmacists may offer an alternative brand 
or cheaper generic equivalent.21 
	
Summary	of	Product	Characteristics	(SPC)	
/Patient	Information	Leaflet	(PIL)	
EU legislation promotes dissemination 
of information, but more enforcement as 
regards the distirubution of SPCs to doctors 
was considered necessary. The dispensing of 
PILs with the medicine pack was also not 
being enforced and practiced by everyone. 
Awareness on the use of medicines could be 
improved by empowering people in line with 
the safeguards of EU legislation. 
POM	and	OTC
Following EU accession, the OTC range 
available became smaller. This was probably 
due to products not being registered and 
due to the new classification of products 
into POM and OTC. This classification may in 
certain cases reduce irrational use, but in 
others it disrupts the usual rational practice. 
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• The pharmaceutical policy arena deals with conflicting goals of maximizing access, 
ensuring quality, minimising costs and promoting rational use of medicines.2
• The evaluation of the change in policies brought about by EU legislation, can drive 
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advocacy of evidence and by helping policy makers think.24  
• EU accession has ensured that medicines available in Malta are of high quality.
• EU legislation had a negative impact on access to medicines in Malta but 
discussions led to reflexive learning and policy making with the aim of improving 
the situation, while maintaining the other benefits of the EU regulatory regime.
• The use of medicine which can seem irrational in certain contexts, may in other 
contexts seem quite rational. 1 
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Both prescribers and patients resist change. 
Patients often could not understand why 
a good medicine to which they were used, 
is no longer available, or why they need a 
prescription to buy it.
Advertising	and	promotion
The fact that industry can market OTCs 
directly to consumers, has increased the 
emphasis on this target group. The ease 
with which the OTCs could be advertised was 
compensating for the reduced availability of 
OTCs. Aggressive advertising was resulting 
in presumably informed consumers asking 
the pharmacist for a specific product rather 
than for advice.
The Legal Notice 80 of 200, 
Medicines Act 200, entitled Medicinal 
Products (Advertising) Regulations governs 
advertising and promotion with the 
healthcare professionals and the public.22 
However, the regulations do not cover the 
communication between pharmaceutical 
companies and patient organizations. This 
could be due to the fine line between 
information and advertising.  
Conclusion
The conflicting goals of access, quality 
and rational use of medicines, make broad 
qualitative and quantitative knowledge 
essential for good pharmaceutical 
policymaking.2 The implementation of EU 
legislation in Malta, caused a decrease 
in the availability and affordability of 
medicines, an improvement in the quality 
of medicines, and conflicting positive and 
negative effects on the rational use of 
medicines. Such contribution to practical 
reason and informed discourse, can be 
appreciated and expanded to reshape and 
make better policies.2  
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